

1 **Staphylococcal superantigens promote bacterial persistence following**  
2 **postoperative surgical site infection**

3

4 Karine Dufresne<sup>1\*</sup>, Stephen W. Tuffs<sup>1,2\*</sup>, Nicholas R. Walton<sup>1</sup>, Katherine J. Kasper<sup>1</sup>, Ivor  
5 Mohorovic<sup>1</sup>, Farah Hasan<sup>1</sup>, Tracey Bentall<sup>3</sup>, David E. Heinrichs<sup>1</sup>, Johan Delpont<sup>4</sup>, Tina S.  
6 Mele<sup>3,5</sup>, and John K. McCormick<sup>1</sup>

7

8 <sup>1</sup> Department of Microbiology and Immunology, University of Western Ontario, London,  
9 Canada

10 <sup>2</sup> Department of Biochemistry and Microbiology, University of Victoria, Victoria, Canada

11 <sup>3</sup> Division of Critical Care Medicine, Department of Medicine, University of Western  
12 Ontario, London, Canada

13 <sup>4</sup> Department of Pathology, University of Western Ontario, London, Canada

14 <sup>5</sup> Division of General Surgery, Department of Surgery, London Health Sciences Centre,  
15 University Hospital, London, Canada

16

17 \*KD and SWT contributed equally to this work.

18

19 Correspondence: John K McCormick, Department of Microbiology and Immunology,  
20 University of Western Ontario, London, Ontario, Canada ([john.mccormick@uwo.ca](mailto:john.mccormick@uwo.ca)).

21 **Abstract**

22 *Staphylococcus aureus* is a predominant cause of postoperative surgical site infections and  
23 persistent bacteremia. Here we describe a patient that following a total knee arthroplasty  
24 subsequently experienced three episodes of *S. aureus* bacteremia over a period of 4  
25 months. The initial blood stream isolate (SAB-0429) was a clonal complex (CC) 5 and  
26 methicillin resistant *S. aureus* (MRSA), whereas two subsequent blood stream isolates  
27 (SAB-0485 and SAB-0495) were CC5 isolates but methicillin sensitive *S. aureus* (MSSA).  
28 The two latter isolates harbored a plasmid encoding three superantigen genes not present  
29 in the primary MRSA isolate. SAB-0485 and SAB-0495 expressed the plasmid encoded  
30 staphylococcal enterotoxin R (SER) exotoxin and demonstrated increased superantigen  
31 activity compared with SAB-0429. Compared to SAB-0429, the latter isolates also  
32 demonstrated an increased bacterial burden in a mouse bacteremia model that was  
33 dependent on increased IFN $\gamma$  production. Curing of the plasmid from SAB-0485 reduced  
34 this virulence phenotype. These findings suggest that the superantigen exotoxins may  
35 provide a selective advantage in chronic postsurgical infections.

36

37 **Keywords.** *Staphylococcus aureus*, superantigen, surgical site infection, bacteremia.

## 38 Introduction

39 *Staphylococcus aureus* is a common human colonizer and opportunistic pathogen capable  
40 of causing a wide array of infections that can range from superficial skin lesions to invasive  
41 infections including endocarditis, osteomyelitis and bacteremia. Fatality rates for *S. aureus*  
42 bacteremia (SAB) in both community and hospital settings are approximately 20-30% [1,2]  
43 and methicillin-resistant *S. aureus* (MRSA) strains are of major concern as treatment with  
44 antibiotics often fail to clear the bacteria within the patients until a correct regimen is  
45 found [3]. *S. aureus* is also an important cause of post-surgical site infections (SSIs) where  
46 infection due to MRSA has been related to a 7-fold increased risk of death, a 35-fold  
47 increased risk of hospital re-admission, and over three weeks of additional hospitalization  
48 [4]. When compared to matched control cases, orthopedic SSIs prolong hospital stays for  
49 an average of 2 weeks, approximately doubling the rates of re-hospitalization, increasing  
50 hospital costs by ~300% [5,6]. Orthopedic SSI can also result in a decreased quality of life  
51 due to increased physical limitations from the infection [5]. For these reasons, *S. aureus*  
52 decolonization strategies of the orthopedic surgical team and of patients have been  
53 implemented and demonstrate a reduction of the total number of surgical site infections  
54 [7–9].

55 Both MRSA and methicillin-sensitive *S. aureus* (MSSA) can survive and persist  
56 during infection by manipulating the host using multiple virulence factors [10], including  
57 a unique family of toxins called superantigens (SAGs) [11]. SAGs trigger large scale  
58 activation of T cells independent of antigen presentation and this aberrant activation can  
59 lead to an overwhelming cytokine storm disease known as toxic shock syndrome [12].  
60 During experimental bloodstream infection, *S. aureus* can survive and proliferate in  
61 organs including the liver and kidney and, in this context, staphylococcal SAGs can  
62 dramatically enhance bacterial burden in the liver through the production of pathogenic  
63 levels of IFN $\gamma$  that impede macrophage activity [13]. Conversely, the role of  
64 staphylococcal SAGs during mucosal colonization is less well understood but these toxins  
65 may function as immunological checkpoints in the nares, a major site of *S. aureus*  
66 colonization [14].

67            In this study, we characterized three consecutive clonal complex 5 (CC5) isolates  
68 of *S. aureus* acquired from the same patient after recurrence of an orthopedic SSI. Strains  
69 were isolated at days 19, 107 and 128 from the original surgical procedure, and the two  
70 latter strains differed from the primary isolate by the presence of a SAg-encoding plasmid.  
71 Following extensive genetic and phenotypic characterization of these isolates, including  
72 experimental bacteremia experiments in mice that are sensitive to human-tropic SAg  
73 activity, our findings suggest that the SAGs contribute to persistence of *S. aureus*  
74 bacteremia associated with SSIs.

75 **METHODS**

76

77 **Human ethics statement**

78 *S. aureus* bacteremia patients admitted to the London Health Sciences Centre were  
79 identified following a positive bacteremia blood culture test. The *S. aureus* isolates  
80 characterized in study were obtained from Victoria Hospital, London, Ontario, Canada,  
81 and delivered to the research laboratory on clinical swabs (Starplex Scientific). Each isolate  
82 was assigned a London Health Sciences Centre-*S. aureus* Bacteremia (SAB) unique number  
83 to maintain the patient anonymity. LHSC-SAB numbers were input into an encrypted  
84 database to be used to cross-reference patient outcomes at the conclusion of the study.  
85 The study was reviewed and approved by the University of Western Ontario Health  
86 Sciences Research Ethics Board (HSREB #105167). For experiments with human peripheral  
87 blood mononuclear cell (PBMC) assays, healthy volunteers were recruited from within the  
88 Department of Microbiology and Immunology at the University of Western Ontario, and  
89 following an outline of the risks, written informed consent was given by each volunteer  
90 before each sample was taken. After sampling, blood was anonymized and no information  
91 regarding the identity of the donor, including sex and age, was retained as per the study  
92 protocol. The study was reviewed and approved by the University of Western Ontario  
93 Health Sciences Research Ethics Board (HSREB #110859).

94

95 **Bacterial strains and growth conditions**

96 *S. aureus* strains were routinely grown aerobically at 37°C in tryptic soy broth (TSB) or  
97 brain heart infusion broth (BHI) with shaking (250 rpm) or on tryptic soy agar (TSA)  
98 supplemented with the appropriate antibiotics as needed. For select experiment, *S.*  
99 *aureus* isolates were spotted onto either 5% sheep blood agar or 5% casein (skim milk)  
100 plates and grown overnight to assess hemolytic or proteolytic activity, respectively.  
101 Growth curves were performed using the Biotek Synergy H4 multimode plate reader  
102 (Agilent). *Escherichia coli* XL1-blue was used for cloning purposes and was grown

103 aerobically at 37°C with shaking (250 rpm) in Luria-Bertani (LB) broth, or on LB agar, with  
104 the appropriate antibiotics.

105

### 106 **Genome sequencing**

107 Total DNA preparations from the three *S. aureus* clinical isolates (herein referred to as  
108 SAB-0429, SAB-0485, and SAB-0495) were sequenced using paired end Illumina and long  
109 read nanopore sequencing at SeqCenter, Pittsburgh, USA. Sequence data were used to  
110 generate *de novo* assemblies using SPAdes v3.15 for both chromosome and plasmid DNA  
111 and annotated using Prokka v1.12. The genome and plasmid assemblies for the isolates  
112 have been deposited at NCBI (Biosamples SAMN42466856, SAMN42466857,  
113 SAMN42466858, PQ014898 and PQ014899). A core SNP alignment was built using snippy  
114 and snippy-core v4.1 (<https://github.com/tseemann/snippy>) using these isolates and a  
115 small selection of other publicly available CC5 sequences from Canada, and a phylogenetic  
116 tree was constructed using FastTree v2.1.10. The presence of previously described SAgS  
117 among the genome sequence data set was established by nucleotide BLAST (blastn) as  
118 implemented in blastable (<https://github.com/bawee/blastable>) using a threshold of 90%  
119 of identical positions to consider a gene present.

120

### 121 **T cell activation assays**

122 *S. aureus* strains were grown in TSB overnight and sub-cultured at 1% into fresh TSB for  
123 18 hours, cells were pelleted, and supernatants were filter sterilized. PBMCs were isolated  
124 using Ficoll-HyPaque Plus gradients (GE Healthcare), washed three times, and  
125 resuspended in complete RPMI (cRPMI) containing RPMI (Invitrogen Life Technologies)  
126 supplemented with 10% fetal bovine serum (FBS) (Wisent), 2mM L-glutamine (Gibco),  
127 1mM sodium pyruvate (Gibco), 100 µM nonessential amino acids (Gibco), 25mM Hepes  
128 (pH 7.2) (Gibco), 100 µg/mL streptomycin, 100 U/mL penicillin (Gibco) and 2 µg/mL  
129 polymyxin B (Gibco). IL-2 concentrations were determined after 18-hours by ELISA  
130 (Invitrogen).

131

## 132 **Proteomic analysis**

133 Bacteria were grown in TSB overnight and sub-cultured in fresh TSB for 18 hours, cells  
134 were pelleted, and supernatants were harvested and normalized to a  $OD_{600} = 1.0$ .  
135 Extracellular proteins were precipitated using 6% trichloroacetic acid for 30 minutes on  
136 ice. Precipitated proteins were washed in acetone and resuspended in 8M urea. Resulting  
137 samples were separated on 12% acrylamide SDS-PAGE gel and analyzed by mass  
138 spectrometry. Mass spectrometry analysis was conducted at the London Regional  
139 Proteomics Centre (University of Western Ontario, London, Canada). Briefly, protein bands  
140 within a range of 15-70 kDa were excised using an Ettan Spot Picker (GE Healthcare Life  
141 Sciences) and digestion was made in-gel using a Waters MASSPrep Automated Digester  
142 (PerkinElmer Inc). Processed samples were pre-mixed with a matrix-assisted laser  
143 desorption ionization (MALDI) matrix and spotted on MALDI target. Sample spots were  
144 analyzed using a 5800 MALDI TOF/TOF System (AB Sciex) in reflectron-positive mode, and  
145 the peptide fingerprint masses were searched against the NCBI database for Gram-  
146 positive bacteria using the MASCOT search engine. Raw mass spectra of the samples not  
147 resulting in highly confident identification were processed and compared with the raw  
148 data of the samples identified with high confidence using the Data Explorer (AB Sciex).

149

## 150 **Mice**

151 Human leukocyte antigen (HLA)-DR4-IE (DRB1\*0401) transgenic mice lacking endogenous  
152 mouse MHC-II on a C57BL/6 background (herein referred to as DR4-B6 mice) [15], or  
153 conventional C57BL/6 mice (herein referred to as B6 mice), were used for *in vivo* infection  
154 experiments. Mice were sex-matched for experiments and were between 8- to 12 weeks  
155 old. DR4-B6 mice were bred within a barrier facility at the University of Western Ontario  
156 and B6 were purchased from Charles River Laboratories. Animals were housed in single-  
157 sex cages to a maximum of 4 animals per cage. Mice were provided water and food *ad*  
158 *libitum* and appropriate environmental enrichment was provided. The animal  
159 experiments followed the Canadian Council on Animal Care Guide to the Care and Use of

160 Experimental Animals and the protocol was approved by the Animal Care Committee at  
161 the University of Western Ontario (Animal Use Protocol #2020-061).

162

### 163 **Bacteremia infection model**

164 Single bacterial colonies were grown in TSB overnight and subcultured at 1% into fresh  
165 TSB and grown to post exponential phase (~3 to 4 hours). The bacterial pellets were  
166 washed once and resuspended in Hank's balanced salt solution (HBSS— Gibco) to an OD<sub>600</sub>  
167 of 0.15 which corresponds to approximately  $5 \times 10^7$  CFU/mL. Mice were injected via the  
168 tail vein with  $\sim 5 \times 10^6$  CFU of *S. aureus* in a total volume of 100  $\mu$ L. Mice were weighed  
169 and monitored daily. At 3 days post infection, mice were euthanized, and the kidneys and  
170 livers were aseptically harvested. Organs were homogenized, plated on mannitol salt agar  
171 (MSA), and incubated at 37 °C overnight. *S. aureus* colonies were enumerated the  
172 following day with a limit of detection determined to be 3 CFU per 10  $\mu$ L.

173 Interferon- $\gamma$  (IFN $\gamma$ ) depletion experiments were performed as previously described  
174 [13]. Briefly, mice were treated with a 250- $\mu$ g dose of anti-IFN- $\gamma$  (cloneXMG1.2, BioXCell),  
175 or a rat IgG1 isotype antibody control (clone HRPN), 18 hours prior to *S. aureus* infection.  
176 All antibody doses were prepared in 100  $\mu$ L PBS and administered by intraperitoneal  
177 injection.

178

### 179 **Curing of the pIB485-like plasmid from *S. aureus* SAB-0485**

180 To help understand the direct contribution of the pIB485-like plasmid to *S. aureus*  
181 persistence, we attempted to cure the plasmid by repeatedly growing the strains at  
182 elevated temperatures but these experiments did not result in plasmid loss. We therefore  
183 took a genetic approach to remove the plasmid where flanking regions of staphylococcal  
184 enterotoxin R (*ser*) gene were PCR amplified, ligated and cloned in pKOR1 integration  
185 plasmid within the *attP* sites of the vector as described [16]. The pKOR1::*ser* plasmid was  
186 sequenced to confirm its integrity (Plasmidsaurus) and was subsequently electroporated  
187 into competent SAB-0485 as described [17]. Following integration of pKOR1::*ser* into the  
188 pIB485-like plasmid, to select against strains harboring the pIB485-like plasmid containing



189 the integrated pKOR::*ser* plasmid, bacteria were treated for 3 days with  
190 anhydrotetracycline (1µg/ml) to induce the anti-sense *secY* counter selection encoded  
191 within pKOR1 [16], with subculturing of bacteria in fresh medium with the supplement  
192 every day. The final culture was serially diluted and incubated on TSA plates overnight.  
193 The colonies were first screened for absence of chloramphenicol resistance from pKOR1  
194 and for absence of ampicillin resistance from pIB485-like. The plasmid-cured antibiotic  
195 sensitive strain was confirmed by PCR.

196

### 197 **Statistical analyses**

198 Statistical analyses were performed using GraphPad Prism 10. A *p* value equal or lower  
199 than 0.05 was considered to be statistically significant. The bacterial burden calculated in  
200 the animal experiments were analyzed using the Kruskal-Wallis test with an uncorrected  
201 Dunn's test for multiple comparisons or Mann-Whitney test.

## 202 RESULTS

### 203 Patient history

204 A patient in their 70s was admitted to London Health Science Center and received a total  
205 right knee arthroplasty, patellaplasty, and bone grafting of the distal femur on the right  
206 side to treat osteoarthritis. Following a successful surgery, the site became infected 19-  
207 days post treatment with a *S. aureus* positive blood culture (strain SAB-0429), and a  
208 second surgery was performed to remove infected tissue. The patient received cefazolin  
209 and vancomycin after the second surgery. The patient re-presented at the clinic 107-days  
210 post initial surgery with an infection in the right knee, again positive for *S. aureus* (strain  
211 SAB-0485). The patient was treated with vancomycin and sulfamethoxazole and  
212 trimethoprim (Septra). An additional sample at the right knee was collected 118 days after  
213 the initial surgery that was positive for *S. aureus* (strain SAB-0495). The patient's antibiotic  
214 regimen was changed to cefazolin, cloxacillin and vancomycin. After this round of  
215 treatment, no further cultures of *S. aureus* were recorded.

216

### 217 Strain analysis indicates the patient was infected with 2 distinct clones of *S. aureus*

218 We next subjected the three SAB isolates to whole genome sequencing and created *de*  
219 *novo* assemblies of each of the isolates to determine genetic relationships. *In silico* multi-  
220 locus sequence type (MLST) analysis indicated that all three isolates were sequence type  
221 (ST) 5 (**Table S1**) belonging to clonal complex (CC) 5. Using a selection of publicly available  
222 CC5 sequences from Canada, we determined that despite being of the same clonal  
223 lineage, these isolates were not closely related, and the SAB-0429 isolate was in a distinct  
224 clade from the SAB-0485 and SAB-0495 isolates (**Figure 1A**). Further using the  
225 Comprehensive Antibiotic Resistance Database (CARD) [18], we were able to confirm that  
226 SAB-0429 was an MRSA encoding the Staphylococcal Cassette Chromosome *mec*  
227 (SCC*mec*) element (**Table S2**). Curiously, the CARD analysis also identified that the SAB-  
228 0485 and SAB-0495 isolates encode the BlaZ beta lactamase, but this was not present in  
229 the SAB-0429 isolate (**Table S2**). These data indicate that the patient was infected first  
230 with a clone of CC5 MRSA that was supplanted by a different CC5 MSSA.

231 **SAB-0485 and SAB-0495 have a unique set of SAg encoded on pIB485-like plasmid**

232 To evaluate if these strains had any difference in pathogenic potential, we assessed the  
233 genome sequencing data to determine the virulence factor composition present in these  
234 isolates. In specific reference to SAg genes, all three isolates were found to encode the  
235 staphylococcal enterotoxin genes *seg*, *sei*, *selM*, *selN*, *selW* and *selX*; however the *sed*, *sej*  
236 and *ser* genes were only in isolates SAB-0485 and SAB-0495. These three SAg have usually  
237 been found encoded together within pIB485-like plasmids [19,20] and the presence of  
238 this plasmid in the two MSSA isolates was confirmed by assembling the plasmid from the  
239 combined long and short sequencing using *de novo* assembly (**Figure 1B**).

240 To evaluate if one or all three SAg were being expressed by SAB-0485 and SAB-  
241 0495, the extracellular proteins produced in bacterial culture from the three bacterial  
242 strains were subjected to proteomic analysis. First, SDS-PAGE analysis confirmed that the  
243 secreted profiles between the MSSA and MRSA isolates were quite different. This was  
244 further confirmed by mass spectrometry analysis (**Table S3**). SAB-0429 produced several  
245 toxins including the pro and mature forms of glycerol-ester hydrolase (Geh), nuclease  
246 (Nuc), leukocidins (LukED) and gamma hemolysins (HlgAB) (**Figure 1C**); however, no SAg  
247 peptides were detected from *S. aureus* SAB-0429. However, from SAB-0485 and SAB-0495  
248 supernatants, the SAg SER was identified (solid arrow, **Figure 1C**). Notably, we also  
249 detected  $\alpha$ -hemolysin (Hla) by mass spectrometry from both SAB-0485 and SAB-0495, but  
250 not SAB-0429 (**Table S3**).

251

252 **SAB-0485 and SAB-0495 produce increased levels of superantigen activity**

253 To better understand how *S. aureus* may have persisted during infection, the three isolates  
254 were subjected to a range of phenotypic tests. First, the growth profile of all three isolates  
255 were assessed in rich bacterial media (tryptone soy broth) and the strains grew similar  
256 (**Figure 2A**). To evaluate if differences in cytolytic toxin expression had an impact,  
257 hemolytic profiles of three isolates were determined by spotted the strains on TSA agar  
258 containing 5% sheep blood. Hemolysis was observed for all three isolates although this  
259 activity was decreased from the SAB-0429 isolate compared to the SAB-0485 and SAB-

260 0495 isolates (**Figure 2B**), consistent with an apparent reduced capacity to produce Hla  
261 (**Table S3**). In parallel, the isolates were spotted on 5% casein hydrolysis plates (skim milk  
262 plates) to examine protease activity although no differences in proteolytic activity were  
263 observed (**Figure 2B**). Next, to evaluate if the presence of the additional plasmid encoded  
264 SAGs correlated with an increased ability to induce higher levels of T cell activation, we  
265 incubated primary human PBMCs with filter sterilized supernatant from each isolate and  
266 measured the production of IL-2. Compared to SAB-0429, both SAB-0485 and SAB-0495  
267 were able to consistently induce T cell activation at lower supernatant dilutions, indicating  
268 that the presence of the pIB485-like plasmid correlated with higher superantigenic  
269 capacity in the two MSSA isolates (**Figure 2C**). Taken together, the genetic and phenotypic  
270 analyses suggest that antibiotic treatment for the initial MRSA infection with SAB-0429  
271 was successful, although the patient became reinfected with a persistent MSSA isolate  
272 that produced larger amounts of virulence promoting toxins.

273

#### 274 **Isolates containing the pIB485-like plasmid persist at higher level in the liver**

275 The increased superantigen activity of the MSSA isolates (**Figure 2C**) may have promoted  
276 persistence of these strains following the second surgery and the relapse of infection in  
277 the patient's knee. To evaluate if the SAB-0485 and SAB-0495 strains exhibited increased  
278 persistence *in vivo* compared to the SAB-0429 isolate, we utilized an experimental model  
279 of bacteremia in transgenic mice that express human MHC-II molecules (DR4-B6) and are  
280 sensitive to SAG function [13,21]. The susceptibility of the DR4-B6 strain to exoproteins  
281 secreted by each *S. aureus* strain was tested by exposing extracted splenocytes with  
282 isolate supernatants and assessing for IL-2 production. Supernatants from both SAB-0485  
283 and SAB-0495 resulted in an increased production of IL-2 compared to SAB-0429,  
284 especially visible at the dilution factor of ~1/250, noting that the more concentrated  
285 supernatants contain active cytolytic toxins that kill the immune cells (**Figure 3A**). To  
286 identify pathogenic differences between these strains during experimental bacteremia,  
287 DR4-B6 mice were intravenously inoculated with the different *S. aureus* isolates and  
288 bacterial burden in the liver and kidneys were assessed 3 days post-inoculation. The

289 bacterial burden in the liver of DR4-B6 mice was increased for both SAB-0485 and SAB-  
290 0495 compared with SAB-0429 (**Figure 3B**), although there were no differences in  
291 bacterial counts in the kidneys (**Figure 3C**). These data suggest that the SAGs encoded on  
292 the pIB485-like plasmid may be involved in promoting the persistence of the latter SAB-  
293 0485 and SAB-0495 isolates compared with the initial SAB-0429 isolate during  
294 bloodstream infection.

295 Hla has also been implicated in liver persistence by *S. aureus* [15]. As this toxin  
296 showed increased expression from the proteomic analysis (**Table S3**) and that phenotypic  
297 assessment showed decreased hemolytic activity for SAB-0429 (**Figure 2B**), it was  
298 important to evaluate a potential role of Hla in the bacteremia model. Conventional  
299 mouse models are sensitive to the activity of this toxin [22]; therefore, we repeated our  
300 bacteremia analysis in conventional B6 mice. Splenocytes from conventional B6 mice were  
301 first co-incubated with supernatants from each isolate which did not induce any  
302 detectable T cell activation, confirming the lack of susceptibility of these mice to SAg  
303 (**Figure 3D**). Next, the experimental bacteremia experiment was repeated in conventional  
304 B6 mice and although there was a trend suggesting increased bacterial recovery from the  
305 liver for the two MSSA isolates, this was not statistically different (**Figure 3E**). As with the  
306 DR4-B6 mouse experiments, there were no obvious differences in bacterial counts  
307 recovered from the kidneys. These collective data suggest that the differences we  
308 observed between the tested *S. aureus* strains was due primarily to the additional SAGs  
309 encoded by SAB-0485 and SAB-0495, rather than the expression of other virulence factors.

310

### 311 **Loss of pIB485-like decreases the bacterial burden in the liver**

312 To determine if the increased bacterial burden within the liver of DR4-B6 mice was due to  
313 the set of SAGs encoded within pIB485-like plasmid, the cured this plasmid from SAB-0485  
314 and this strain was evaluated using the bacteremia model in DR4-B6 mice. First, the  
315 supernatants from either wildtype *S. aureus* SAB-0485 or the isogenic strain lacking the  
316 pIB485-like plasmid were tested for IL-2 production from DR4-B6 splenocytes and a  
317 decreased stimulation of PBMC was observed with the plasmid cured strain (**Figure 4A**).

318 We hypothesized that this decrease in T cell stimulation would correlate with decreased  
319 bacterial burden within the liver in the DR4-B6 bloodstream infection model. Indeed, in  
320 absence of the pIB485-like plasmid, this strain reached a lower bacterial burden in the  
321 liver of the mice compared to wild-type SAB-0429 (**Figure 4B**).

322

### 323 **pIB485-like encoded SAGs promote a pathogenic IFN $\gamma$ response**

324 We previously demonstrated that SAGs could promote a pathogenic IFN $\gamma$  response that  
325 modifies macrophage responses and allows *S. aureus* to persist and replicate more  
326 effectively within macrophages [13]. This mechanism could potentially explain why the  
327 two MSSA isolates persisted for longer in the patient compared with the MRSA clone  
328 despite antibiotic treatment. To test this hypothesis, we utilized an IFN $\gamma$  depletion  
329 protocol in DR4-B6 mice prior to infection with either SAB-0429 or SAB-0485, and bacterial  
330 liver and kidney burdens were enumerated at 72 hours post-infection (**Figure 5A**). For  
331 infections with *S. aureus* SAB-0429, depletion of IFN $\gamma$  had no measurable impact on  
332 bacterial recovery from the liver or kidneys compared to the isotype antibody treatment  
333 control. For animals infected with *S. aureus* SAB-0485, IFN $\gamma$  depletion resulted in a  
334 significant reduction in bacterial recovery from the liver (**Figure 5B**) but again did not alter  
335 kidney burden (**Figure 5C**). Importantly, the IFN $\gamma$  depletion for the SAB-0485 isolate  
336 reduced bacterial recovery in the liver that was equivalent to the SAB-0429 isolate,  
337 indicating that removing the pathogenic IFN $\gamma$  production mitigated the activity of the  
338 plasmid encoded SAGs. Together this demonstrates that the pIB485-like encoded SAGs can  
339 promote excessive IFN $\gamma$  production and promote bacterial persistence of these isolates  
340 during experimental bacteremia.

341 **Discussion**

342 *S. aureus* infections acquired in the hospital setting can result in life-threatening  
343 disease and poor outcomes which may be further complicated by antimicrobial resistance.  
344 In addition, microbial mechanisms that promote persistence during infection can further  
345 exacerbate disease. In this work, we encountered MSSA isolates of *S. aureus* that were  
346 able to persist in a patient despite antimicrobial therapy. Based on comparisons with the  
347 earlier MRSA isolate from the same patient, and combined with experimental infection  
348 models, we were able to determine that the increased persistence of these MSSA strains  
349 was associated with the production of plasmid-encoded SAg toxins. We initially  
350 considered that this may be an example of in-patient evolution, but genome sequencing  
351 determined that although the main differentiating determinant of the strains was the  
352 pIB485-like plasmid, the SAB-0429 isolate was not ancestral to the SAB-0485 and SAB-  
353 0495 isolates (**Figure 1A**). Therefore, this patient may have been colonized simultaneously  
354 at the injury site with different *S. aureus* clones or was subsequently infected during the  
355 period between presentations at the clinic.

356 All three *S. aureus* isolates were identified to be members of the CC5 clade. This  
357 clonal complex is a clinically important group and frequently isolated from nosocomial  
358 infections. In Ontario and Canada, CC5 has been related with community-associated  
359 infections, especially in the case of MRSA isolates [23]. Strains from CC5 also harbor high  
360 variability in their SAg complement, and this can include the presence or absence of the  
361 pIB485-like plasmid in both MRSA and MSSA lineages of this clonal complex [23]. Indeed,  
362 the pIB485-like plasmid contributed to this genetic variability between the MRSA isolates  
363 in this study. Interestingly, multiple experiments growing *S. aureus* SAB-0485 at elevated  
364 temperatures did not result in curing of this plasmid, suggesting this is a stable genetic  
365 element in *S. aureus* that may be associated with persistent infection and worse patient  
366 outcome.

367 The MSSA isolates we identified were able to survive in the patient in between  
368 disease episodes and cause resurgence of bacteremia despite high levels of antibiotic  
369 stress. Subsequently, we were able to demonstrate that the MSSA isolates were persisting

370 in experimental *in vivo* bacteremia model, in part, by inducing a pathogenic IFN $\gamma$  response  
371 (**Figure 5**). We previously demonstrated that this mechanism could support the replication  
372 of *S. aureus* inside macrophages and allow the bacteria to persist *in vivo*. Further, being  
373 able to persist and replicate within a macrophage may effectively contribute to avoidance  
374 of killing by antibiotics [13]. Other mechanisms of persistence within macrophages have  
375 been previously described for many bacterial pathogens; however these mechanisms  
376 usually include a ‘persister-type’ phenotype [24,25]. In the current study, *S. aureus*  
377 persistence may allow survival of the bacterium independent of this persister phenotype  
378 as the quick recovery of bacteria following the organs collection suggests that *S. aureus*  
379 was in a replicative state in the animal. Although both SAB-0485 and SAB-0495 harbored  
380 several SA $\gamma$  genes, only SER was detected from *in vitro* conditions by proteomics, and we  
381 demonstrated that this impacted the bacterial burden within the liver during bacteremia.  
382 Altogether, SER demonstrated similar characteristics to SEA [21], SEB and SEC [13], and  
383 SEI-W [26] produced from other *S. aureus* strains in bloodstream infections by enhancing  
384 persistence in the liver.

385 Due to limitations in sampling, we were unable to fully establish how this patient  
386 experienced infections with two distinct clones of *S. aureus*. Samples at admission were  
387 not retained so we were unable to assess if this patient was nasally colonized prior to  
388 infection, and if this was the source of the surgical complication. During the disease, both  
389 co-infection with the MSSA and MRSA clones is possible as well as hematological spread  
390 from another source. In both scenarios, a virulence mechanism that enhanced survival in  
391 macrophages would have provided a selective advantage for the MSSA strains in the  
392 patient and may have led to the clearance of the MRSA clone.

393 This study highlights how virulence factors may provide an evolutionary advantage  
394 to *S. aureus* strains in certain patient settings. Beyond classical antimicrobial resistance  
395 mechanisms, *S. aureus* is also potent at manipulating its environment and shielding itself  
396 from the immune system. Although these findings do not diminish the concerns around  
397 antimicrobial resistance, this research demonstrates the importance of considering the



398 niche of *S. aureus*, the range of virulence factors encoded in its genome, and factors that  
399 are produced by the bacterium during infection that contribute to disease.

400

401 **Financial support.** This work was supported by an operating grant from the Canadian  
402 Institutes of Health Research (CIHR) (PJT-166050) to S.W.T, T. S. M. and J.K.M and D.E.H  
403 acknowledges funding from CIHR grant PJT-168842.

## 404 References

- 405 1. Van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of  
406 Mortality in *Staphylococcus aureus* Bacteremia. Clin Microbiol Rev. **2012**;  
407 25(2):362–386.
- 408 2. Lam JC, Stokes W. The Golden Grapes of Wrath – *Staphylococcus aureus*  
409 Bacteremia: A Clinical Review. The American Journal of Medicine. **2023**; 136(1):19–  
410 26.
- 411 3. Vestergaard M, Frees D, Ingmer H. Antibiotic Resistance and the MRSA Problem.  
412 Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Braunstein M, Rood JI, editors.  
413 Microbiol Spectr. **2019**; 7(2):7.2.18.
- 414 4. Anderson DJ, Kaye KS, Chen LF, et al. Clinical and Financial Outcomes Due to  
415 Methicillin Resistant *Staphylococcus aureus* Surgical Site Infection: A Multi-Center  
416 Matched Outcomes Study. PLoS ONE. **2009**; 4(12):e8305.
- 417 5. Whitehouse JD, Friedman ND, Kirkland KB, Richardson WJ, Sexton DJ. The Impact of  
418 Surgical-Site Infections Following Orthopedic Surgery at a Community Hospital and  
419 a University Hospital Adverse Quality of Life, Excess Length of Stay, and Extra Cost.  
420 Infect Control Hosp Epidemiol. **2002**; 23(4):183–189.
- 421 6. Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-Resistant Pathogens Associated  
422 With Healthcare-Associated Infections: Annual Summary of Data Reported to the  
423 National Healthcare Safety Network at the Centers for Disease Control and  
424 Prevention, 2006–2007. Infect Control Hosp Epidemiol. **2008**; 29(11):996–1011.
- 425 7. Portigliatti Barbos M, Mognetti B, Pecoraro S, Picco W, Veglio V. Decolonization of  
426 orthopedic surgical team *S. aureus* carriers: impact on surgical-site infections. J  
427 Orthopaed Traumatol. **2010**; 11(1):47–49.
- 428 8. Wilcox MH, Hall J, Pike H, et al. Use of perioperative mupirocin to prevent  
429 methicillin-resistant *Staphylococcus aureus* (MRSA) orthopaedic surgical site  
430 infections. Journal of Hospital Infection. **2003**; 54(3):196–201.
- 431 9. Bode LGM, Kluytmans JAJW, Wertheim HFL, et al. Preventing Surgical-Site Infections  
432 in Nasal Carriers of *Staphylococcus aureus*. N Engl J Med. **2010**; 362(1):9–17.
- 433 10. Horváth A, Dobay O, Sahin-Tóth J, et al. Characterisation of antibiotic resistance,  
434 virulence, clonality and mortality in MRSA and MSSA bloodstream infections at a  
435 tertiary-level hospital in Hungary: a 6-year retrospective study. Ann Clin Microbiol  
436 Antimicrob. **2020**; 19(1):17.

- 437 11. Tuffs SW, Dufresne K, Rishi A, Walton NR, McCormick JK. Novel insights into the  
438 immune response to bacterial T cell superantigens. *Nat Rev Immunol.* **2024**;  
439 24:417–434.
- 440 12. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial  
441 superantigens: An update. *Annu Rev Microbiol.* **2001**; 55(1):77–104.
- 442 13. Tuffs SW, Goncheva MI, Xu SX, et al. Superantigens promote *Staphylococcus aureus*  
443 bloodstream infection by eliciting pathogenic interferon-gamma production. *Proc*  
444 *Natl Acad Sci USA. Proceedings of the National Academy of Sciences*; **2022**;  
445 119(8):e2115987119.
- 446 14. Xu S, Kasper K, Zeppa J, McCormick J. Superantigens modulate bacterial density  
447 during *Staphylococcus aureus* nasal colonization. *Toxins.* **2015**; 7(5):1821–1836.
- 448 15. Surewaard BGJ, Thanabalasuriar A, Zeng Z, et al.  $\alpha$ -Toxin induces platelet  
449 aggregation and liver injury during *Staphylococcus aureus* sepsis. *Cell host &*  
450 *microbe.* NIH Public Access; **2018**; 24(2):271-284.e3.
- 451 16. Bae T, Schneewind O. Allelic replacement in *Staphylococcus aureus* with inducible  
452 counter-selection. *Plasmid.* **2006**; 55(1):58–63.
- 453 17. Monk IR, Shah IM, Xu M, Tan M-W, Foster TJ. Transforming the untransformable:  
454 Application of direct transformation to manipulate genetically *Staphylococcus*  
455 *aureus* and *Staphylococcus epidermidis*. Novick RP, editor. *mBio. American Society*  
456 *for Microbiology*; **2012**; 3(2).
- 457 18. Alcock BP, Huynh W, Chalil R, et al. CARD 2023: expanded curation, support for  
458 machine learning, and resistome prediction at the Comprehensive Antibiotic  
459 Resistance Database. *Nucleic Acids Res.* **2023**; 51(D1):D690–D699.
- 460 19. Bayles KW, Iandolo JJ. Genetic and molecular analyses of the gene encoding  
461 staphylococcal enterotoxin D. *J Bacteriol.* **1989**; 171(9):4799–4806.
- 462 20. Omoe K, Hu D-L, Takahashi-Omoe H, Nakane A, Shinagawa K. Identification and  
463 characterization of a new staphylococcal enterotoxin-related putative toxin  
464 encoded by two kinds of plasmids. *Infect Immun.* **2003**; 71(10):6088–6094.
- 465 21. Xu SX, Gilmore KJ, Szabo PA, et al. Superantigens subvert the neutrophil response  
466 to promote abscess formation and enhance *Staphylococcus aureus* survival in vivo.  
467 *Infect Immun.* **2014**; 82(9):3588–98.
- 468 22. Bubeck Wardenburg J, Bae T, Otto M, DeLeo FR, Schneewind O. Poring over pores:  
469  $\alpha$ -hemolysin and Panton-Valentine leukocidin in *Staphylococcus aureus* pneumonia.  
470 *Nat Med.* **2007**; 13(12):1405–1406.

- 471 23. Guthrie JL, Teatero S, Hirai S, et al. Genomic Epidemiology of Invasive Methicillin-  
472 Resistant *Staphylococcus aureus* Infections Among Hospitalized Individuals in  
473 Ontario, Canada. *The Journal of Infectious Diseases*. **2020**; 222(12):2071–2081.
- 474 24. Dadole I, Blaha D, Personnic N. The macrophage–bacterium mismatch in persister  
475 formation. *Trends in Microbiology*. **2024**; :S0966842X24000490.
- 476 25. Fauerharmel-Nunes T, Flannagan RS, Goncheva MI, et al. MRSA Isolates from  
477 Patients with Persistent Bacteremia Generate Nonstable Small Colony Variants *In*  
478 *Vitro* within Macrophages and Endothelial Cells during Prolonged Vancomycin  
479 Exposure. Torres VJ, editor. *Infect Immun*. **2023**; 91(1):e00423-22.
- 480 26. Vrieling M, Tuffs SW, Yebra G, et al. Population analysis of *Staphylococcus aureus*  
481 reveals a cryptic, highly prevalent superantigen SEIW that contributes to the  
482 pathogenesis of bacteremia. Projan SJ, editor. *mBio*. **2020**; 11(5):e02082-20.
- 483

484 **Figure legends**

485

486 **Figure 1. The initial methicillin-resistant *S. aureus* SAB-0429 isolate is genetically distinct**

487 **from methicillin-sensitive *S. aureus* SAB-0485 and SAB-0495 isolates.** (A) Phylogenetic

488 tree of *S. aureus* CC5 strains including isolates SAB-0429, SAB-0485 and SAB-0495. Core

489 SNPs (single nucleotide polymorphisms) were identified using Snippy in the three patient

490 isolates and a small selection of other publicly available CC5 sequences from Canada. A

491 maximum likelihood phylogeny was constructed from the aligned SNPs using FastTree

492 v2,1,10. (B) The sequence of the pIB485-like plasmid found in both *S. aureus* SAB-0485

493 and SAB-0495 is presented with its main characteristics (e.g. *bla* genes and superantigen-

494 encoding genes). (C) Exoprotein profiles from *S. aureus* SAB-0429, SAB-0485 and SAB-0495

495 visualized on SDS-PAGE. Open arrows indicated virulence factors found in all three isolates

496 and the solid arrow indicates SER that was only found in SAB-0485 and SAB-0495.

497

498 **Figure 2. Phenotypic analyses demonstrate enhance superantigen activity from *S.***

499 ***aureus* SAB-0485 and SAB-0495 compared to SAB-0429.**

500 (A) The three *S. aureus* patient isolates were grown in TSB for 24 hours with agitations in

501 a multimode plate reader and their optical density at 600 nm was monitored every hour.

502 Each data point represents the mean of three independent experiments. (B). Hemolytic

503 and proteolytic activity of each isolate assessed on 5% sheep blood TSA plates and skim

504 milk agar plate, respectively. The image is a representative image of experiments

505 replicated at least three times. (C) IL-2 production from supernatants from each isolate

506 grown in TSB for 18 hours. Supernatants were filter-sterilized before exposure to human

507 PBMCs and IL-2 concentrations were measured by ELISA. Each data point represents the

508 mean  $\pm$  SEM of three independent experiments using different donors.

509

510 **Figure 3. *S. aureus* isolates SAB-0485 and SAB-0495 containing the pAB485-like plasmid**

511 **persist at a higher bacterial counts compared to SAB-0429 in a SAg-sensitive model of**

512 **bacteremia. DR4-B6 (A) or B6 (D) splenocytes were isolated and challenged against**

513 supernatant issued from each bacterial isolate and IL-2 production from stimulated cells  
514 was measure by ELISA. Data presented is the mean of three independent experiments  
515  $\pm$ SD. Each isolate was intravenously injected at  $5 \times 10^7$  CFU/mL to DR4-B6 (B&C) or B6  
516 (E&F) animals and bacterial burden of both kidneys (B&E) and liver (C&F) was assessed 3  
517 days post-infection. Each dot represents one animal. The results are represented as the  
518 geometric mean of at least 8 biological replicates  $\pm$  geometric SD. Significant differences  
519 were determined using the Kruskal–Wallis test with the uncorrected Dunn’s test for  
520 multiple comparisons (\*P < 0.05).

521

522 **Figure 4. Loss of the pIB485-like plasmid in the SAB-0485 isolate demonstrates a**  
523 **decreased bacterial burden in the liver.** (A) B6-DR4 splenocytes were isolated and  
524 challenged against supernatant issued from each bacterial strain (SAB-0485 or SAB-0485  
525 without plasmid). The graph represents murine IL-2 quantification during at least three  
526 independent experiments. (B) The same strains were intravenously injected to DR4-B6  
527 animals to perform the bacteremia model and the bacterial burden in the liver is  
528 represented as the geometric mean of at least 7 animals  $\pm$  geometric SD. Each dot  
529 represents one mouse. Significant differences were determined using Mann Whitney test  
530 (\*P < 0.05).

531

532 **Figure 5. Depletion of Interferon gamma eliminates SER-mediated bacterial persistence**  
533 **during *S. aureus* bacteremia.** (A) The bacteremia model was repeated with the isolates  
534 SAB-0429 and SAB-0485 after intraperitoneally injecting the animal with either depleting  
535 antibodies for IFN $\gamma$  or an isotype control 18 hours before *S. aureus* intravenous challenge.  
536 Both the kidneys (B) and the liver (C) were collected and homogenized for bacterial  
537 burden. The results are represented as the geometric mean of at least 8 biological  
538 replicates  $\pm$  geometric SD. Significant differences were determined using the Kruskal–  
539 Wallis test with the uncorrected Dunn’s test for multiple comparisons (\*P < 0.05).




Figure 1.




Figure 2.






Figure 3.




Figure 4.




Figure 5.